'Consistent with the TriTAC mechanism of action, we observed T cell activation and cytokine induction with HPN424 treatment, which prompted us to explore the use of dexamethasone as a premedication to limit potential adverse events,' said Natalie Sacks, M.D., Chief Medical Officer of Harpoon Therapeutics.
In April, Harpoon advanced its second TriTAC, HPN536, a mesothelin-targeting T cell engager, into the clinic and dosed the first patient in a Phase 1/2a clinical trial for ovarian and other mesothelin-expressing solid tumors.
Unlike MSE Tritac
, Win-T will serve smaller groups each with its own local network made up of datalinks and JTRS radios.
Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies.
Harpoon recently announced its second technology platform, ProTriTAC, that applies a prodrug concept to TriTAC in order to create T cell engagers that are designed to be preferentially active in the tumor microenvironment.
Harpoon's TriTAC platform was designed to advance the therapeutic potential of T cell engagers, with a long half-life extended format.
Harpoon is developing a pipeline of four wholly owned TriTAC product candidates.
Harpoon has also invented a ProTriTAC platform that applies a prodrug concept to TriTAC
to create T cell engagers designed to be preferentially active in the tumor microenvironment.
Harpoon Therapeutics is seeking to develop a robust pipeline of TriTAC
Harpoon is developing a robust pipeline of TriTAC
Under the terms of the agreement, Harpoon will engineer TriTAC
molecules directed against selected cancer targets using its proprietary platform, evaluate the molecules for pharmacologic properties, and provide AbbVie the right to pursue further development and commercialization of these molecules.
Harpoon's first clinical candidate, HPN424, is a prostate-specific membrane antigen -targeting TriTAC
. HPN424 is in development for the treatment of metastatic prostate cancer and is expected to enter Phase 1 clinical trials in 2018.